Lactobacillus casei ： Antibiotic-Associated Diarrhea (AAD)
CSome evidence for AAD prevention in hospitalized elderly patients (PLACIDE trial was negative for primary outcome but showed trends).
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dlactobacillus\u002Dcasei\u0026condition\u003Dantibiotic\u002Dassociated\u002Ddiarrhea';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
C
結論
Some evidence for AAD prevention in hospitalized elderly patients (PLACIDE trial was negative for primary outcome but showed trends).
Key Study Findings
In Vitro
Complex probiotics alleviate ampicillin-induced antibiotic-associated diarrhea in mice.
Dose: 4-strain probiotic mixture
vs: Ampicillin-induced AAD model
Outcome: Gut microbiota recovery and immune modulation
効果: None
None
対象集団: Ampicillin-induced AAD mouse model
Meta-Analysis
n=692
Which probiotic has the best effect on preventing Clostridium difficile-associated diarrhea? A systematic review and …
Dose: None
vs: Control group
Outcome: the incidence rates of AAD and CDAD, and …
効果: OR 0.39,
None
対象集団: Diarrhea patients
Randomized Controlled Trial
n=314
4.3 weeks
Double-blind
Probiotic Yogurt for the Prevention of Antibiotic-associated Diarrhea in Adults: A Randomized Double-blind Placebo-controlled Trial.
Dose: None
vs: Placebo
Outcome: Bowel function
効果: None
p=0.30
対象集団: None
Systematic Review
n=228
Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis.
Dose: None
vs: None
Outcome: Diarrhea outcomes
効果: None
None
対象集団: None
Controlled Clinical Trial
n=32
4.3 weeks
Open-label
Feasibility of a Lactobacillus casei Drink in the Intensive Care Unit for Prevention of Antibiotic …
Dose: 10 billion L. casei, 2 bottles/day
vs: Contemporary matched controls
Outcome: Safety, feasibility, AAD incidence
効果: None
None
対象集団: ICU patients on antibiotics
Meta-Analysis
n=9569
Comparative efficacy and tolerability of probiotics for antibiotic-associated diarrhea: Systematic review with network meta-analysis.
Dose: None
vs: Placebo/no probiotic
Outcome: Prevention of antibiotic-associated diarrhea
効果: LGG OR 0.28 (0.17-0.47) for AAD prevention
None
対象集団: Patients on antibiotics
Key Statistics
3
研究数
500
参加者数
↑
Positive
C
グレード
Referenced Papers
Frontiers in microbiology
2023
21 件の引用
Journal of digestive …
2020
43 件の引用
Journal of clinical …
2019
17 件の引用
Frontiers in medicine
2018
450 件の引用
United European gastroenterology …
2018
66 件の引用
Nutrients
2018
50 件の引用
F1000Research
2016
63 件の引用
Antibiotics (Basel, Switzerland)
2015
104 件の引用
Clinical infectious diseases …
2015
59 件の引用
World journal of …
2014
73 件の引用
Savings from the use of a probiotic formula in the prophylaxis of antibiotic-associated diarrhea.
Other
Journal of medical …
2012
28 件の引用
Revista da Sociedade …
2012
13 件の引用
Journal of clinical …
2011
432 件の引用
The American journal …
2010
313 件の引用
Canadian journal of …
2007
182 件の引用
Acta paediatrica Taiwanica …
2004
6 件の引用
International journal of …
2000
181 件の引用
The Journal of …
1999
559 件の引用
Anaerobe
1997
40 件の引用
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
一般的な使用量
- general:
- 1-10 billion CFU/day
- aadprevention:
- 6.5 billion CFU/day (Shirota strain)
- immunesupport:
- 10 billion CFU/day
上限量： Well-tolerated up to 20 billion CFU/day in clinical trials
研究で検討された用量
| 用量 | 期間 | 効果 | N |
|---|---|---|---|
| 4-strain probiotic mixture | -- | Positive | -- |
| None | -- | Positive | 692 |
| None | 4.3 weeks | Neutral | 314 |
| None | -- | Mixed | 228 |
| 10 billion L. casei, 2 bottles/day | 4.3 weeks | Positive | 32 |
| None | -- | Positive | 9569 |
| None | -- | Mixed | -- |
| None | -- | Positive | -- |
推奨摂取タイミング： With or without food; consistent daily timing recommended
Safety & Side Effects
報告されている副作用
- ⚠ Mild gas and bloating during initial use
- ⚠ Occasional loose stools
- ⚠ Rare dairy-related reactions in lactose-sensitive individuals
- ⚠ Very rare: bacteremia in immunocompromised individuals
既知の相互作用
- ● Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
- ● Immunosuppressants (theoretical risk in immunocompromised patients)
耐容上限摂取量： Well-tolerated up to 20 billion CFU/day in clinical trials
サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。
Frequently Asked Questions
Does Lactobacillus casei help with Antibiotic-Associated Diarrhea (AAD)?
Based on 3 studies with 500 participants, there is limited but promising evidence that Lactobacillus casei may support Antibiotic-Associated Diarrhea (AAD) management. Our evidence grade is C (Some Evidence).
How much Lactobacillus casei should I take for Antibiotic-Associated Diarrhea (AAD)?
Studies have used various dosages. A commonly studied range is 1-10 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Lactobacillus casei?
Reported side effects may include Mild gas and bloating during initial use, Occasional loose stools, Rare dairy-related reactions in lactose-sensitive individuals, Very rare: bacteremia in immunocompromised individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Lactobacillus casei and Antibiotic-Associated Diarrhea (AAD)?
We rate the evidence as Grade C (Some Evidence). This rating is based on 3 peer-reviewed studies with 500 total participants. The overall direction of effect is positive.
Related Evidence
に関する他の成分： Antibiotic-Associated Diarrhea (AAD)
FDAに関する免責事項: これらの記述は米国食品医薬品局（FDA）による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。